Concepedia

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study

Fabio Ciceri, Chiara Bonini, Maria Teresa Lupo Stanghellini, Attilio Bondanza, Catia Traversari, Monica Salomoni, Lucia Turchetto, Scialini Colombi, Massimo Bernardi, Jacopo Peccatori,

The Lancet Oncology · 2009 · 484 citations · 35 references

References

35

CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S

Harold Glucksberg, Rainer Storb, A Fefer et al. · Transplantation · 1974 · 3.7K citations

Medicine, Hematology, Immunology +14

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants

Loredana Ruggeri, Marusca Capanni, Elena Urbani et al. · Science · 2002 · 3.4K citations

Life Sciences, Hematology, Immunology +17

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Katarina Le Blanc, Ida Rasmusson, Berit Sundberg et al. · The Lancet · 2004 · 2.7K citations

Life Sciences, Immunology, Surgery +12

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

Katarina Le Blanc, Francesco Frassoni, Lynne M. Ball et al. · The Lancet · 2008 · 2.7K citations

Life Sciences, Immunology, Regenerative Medicine +11